Second Phase 2 clinical trial initiated for fatty liver disease with advanced fibrosis
0 Comments , in Article
Written by Peter G. Traber, M.D. on September 16, 2015 As a company, we are focused on developing a therapy for patients with non-alcoholic steatohepatitis (NASH), or fatty liver disease,...
Read More